{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:10:44Z","timestamp":1772165444716,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe a complex case of ocular tuberculosis reactivation with anterior uveitis, choroiditis and inflammatory choroidal neovascular membrane (CNVM) following immune checkpoint inhibitor (ICPI) treatment of malignant mucosal melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective collection of medical history, clinical findings and multimodal imaging with literature review of the topic was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 52-year-old Romanian female developed reduced vision and photophobia after three cycles of ICPI therapy comprised of ipilimumab and nivolumab. Bilateral anterior uveitis, multiple left eye choroidal lesions and a CNVM were confirmed using slit-lamp examination with ancillary multimodal imaging. Retinal changes in the right eye as well as a history of previously treated posterior uveitis and high-risk ethnicity increased clinical suspicion for ocular tuberculosis (TB) reactivation. The diagnosis was confirmed by TB positivity on polymerase chain reaction (PCR) analysis of lung aspirate followed by significant clinical improvement on systemic anti-tubercular therapy (ATT), systemic steroids and anti-vascular endothelial growth factor (VEGF) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICPIs can cause a myriad of ocular issues, both by primary immunomodulatory effects as well as secondary reactivation of latent disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-023-00374-x","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T17:01:57Z","timestamp":1702918917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tuberculosis reactivation demonstrated by choroiditis and inflammatory choroidal neovascular membrane in a patient treated with immune checkpoint inhibitors for malignant mucosal melanoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Melissa L.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"issue":"17","key":"374_CR1","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P (2019) Immune checkpoint inhibitors: basics and challenges. Curr Med Chem 26(17):3009\u20133025","journal-title":"Curr Med Chem"},{"issue":"2","key":"374_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD et al (2022) Long-term outcomes with Nivolumab Plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced Melanoma. J Clin Oncol 40(2):127\u2013137","journal-title":"J Clin Oncol"},{"key":"374_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2020.00091","volume":"10","author":"AR Almutairi","year":"2020","unstructured":"Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I (2020) Potential immune-related adverse events associated with monotherapy and combination therapy of Ipilimumab, Nivolumab, and Pembrolizumab for advanced Melanoma: a systematic review and meta-analysis. Front Oncol 10:91. https:\/\/doi.org\/10.3389\/fonc.2020.00091","journal-title":"Front Oncol"},{"issue":"2","key":"374_CR4","first-page":"140","volume":"24","author":"E Papavasileiou","year":"2014","unstructured":"Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM (2014) Ipilimumab-induced ocular and orbital inflammation-a case series and review of the literature. Ocul Immunol Inflamm 24(2):140\u2013146","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"374_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5588\/ijtld.18.0270","volume":"23","author":"AL Golli","year":"2019","unstructured":"Golli AL, Nitu MF, Turcu F, Popescu M, Ciobanu-Mitrache L, Olteanu M (2019) Tuberculosis remains a public health problem in Romania. Int J Tuberc Lung Dis 23(2):226\u2013231","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"374_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.nmd.2020.02.013","volume":"30","author":"M Garibaldi","year":"2020","unstructured":"Garibaldi M, Calabro F, Merlonghi G et al (2020) Immune Checkpoint Inhibitors (ICIs)- related ocular myositis. Neuromuscul Disord 30(5):420\u2013423","journal-title":"Neuromuscul Disord"},{"key":"374_CR7","first-page":"139","volume":"12","author":"CW Yu","year":"2022","unstructured":"Yu CW, Yau M, Mezey N, Joarder I, Micieli JA (2022) Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review eye. Brain 12:139\u2013167","journal-title":"Brain"},{"issue":"6","key":"374_CR8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/09273948.2019.1610460","volume":"28","author":"E Tsui","year":"2020","unstructured":"Tsui E, Gonzales JA (2020) Retinal vasculitis associated with Ipilimumab. Ocul Immunol Inflamm 28(6):868\u2013870","journal-title":"Ocul Immunol Inflamm"},{"key":"374_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1001\/jamaophthalmol.2016.2944","volume":"134","author":"P Roberts","year":"2016","unstructured":"Roberts P, Fishman GA, Joshi K, Jampol LM (2016) Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol 134:1184\u20131188","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"374_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1159\/000520416","volume":"12","author":"K Minami","year":"2022","unstructured":"Minami K, Egawa M, Kajita K, Murao F, Mitamura Y (2022) A case of Vogt-Koyanagi-Harada disease-like Uveitis induced by Nivolumab and Ipilimumab combination therapy. Case Rep Ophthalmol 12(3):952\u2013960","journal-title":"Case Rep Ophthalmol"},{"issue":"5","key":"374_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O (2017) Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 5(5):694\u2013700","journal-title":"Clin Case Rep"},{"issue":"3","key":"374_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/01658107.2019.1566385","volume":"44","author":"KA Jaben","year":"2019","unstructured":"Jaben KA, Francis JH, Shoushtari AN, Abramson DH (2019) Isolated Abducens nerve palsy following Pembrolizumab. Neuroophthalmology 44(3):182\u2013185","journal-title":"Neuroophthalmology"},{"issue":"3","key":"374_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","volume":"31","author":"T Fang","year":"2019","unstructured":"Fang T, Maberley DA, Etminan M (2019) Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol 31(3):319\u2013322","journal-title":"J Curr Ophthalmol"},{"issue":"1","key":"374_CR14","doi-asserted-by":"publisher","first-page":"itac012","DOI":"10.1093\/immadv\/ltac012","volume":"2","author":"TR Katsumoto","year":"2022","unstructured":"Katsumoto TR, Wilson KL, Giri VK, Zhu H, Anand S, Ramchandran KJ, Martin BA, Yunce M, Muppidi S (2022) Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity? Immunother Adv 2(1):itac012. https:\/\/doi.org\/10.1093\/immadv\/ltac012","journal-title":"Immunother Adv"},{"key":"374_CR15","doi-asserted-by":"publisher","first-page":"e52668","DOI":"10.7554\/eLife.52668","volume":"9","author":"LB Tezera","year":"2020","unstructured":"Tezera LB, Bielecka MK, Ogongo P, Walker NF, Ellis M, Garay-Baquero DJ, Thomas K, Reichmann MT, Johnston DA, Wilkinson KA et al (2020) Ant-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1. eLife 9:e52668 PMID:32091388","journal-title":"eLife"},{"key":"374_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12348-022-00282-6","volume":"12","author":"I Papasavvas","year":"2022","unstructured":"Papasavvas I, Jeannin B, Herborth CP (2022) Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease. J Ophthalmic Inflamm Infect 12:7","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"374_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ophtha.2020.01.008","volume":"128","author":"R Agrawal","year":"2020","unstructured":"Agrawal R, Testi I, Mahajan S, Yuen YW et al (2020) Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 1. Ophthalmol 128(2):266\u2013276","journal-title":"Ophthalmol"},{"key":"374_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1183\/09031936.00114810","volume":"37","author":"M Sester","year":"2011","unstructured":"Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB et al (2011) Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Resp J 37:100\u2013111","journal-title":"Eur Resp J"},{"issue":"6","key":"374_CR19","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41433-020-01144-y","volume":"35","author":"MA Abouammoh","year":"2021","unstructured":"Abouammoh MA, De Simone L, Almousa AN, Al-Dossari M, Herbort CP, Abu El-Asrar AM (2021) Indocyanine green angiographic findings in presumed intraocular tuberculosis. Eye (Lond) 35(6):1680\u20131687","journal-title":"Eye (Lond)"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-023-00374-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T05:03:00Z","timestamp":1702962180000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-023-00374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1186\/s12348-023-00374-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3342793\/v1","asserted-by":"object"}]},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"10 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This report adheres to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish individual details and images was obtained from the patient\u2019s next of kin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}